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Abstract
Introduction: Ornithine transcarbamylase deficiency is the most common hereditary urea cycle defect. It is
inherited in an X-linked manner and classically presents in neonates with encephalopathy and hyperammonemia
in males. Females and males with hypomorphic mutations present later, sometimes in adulthood, with episodes
that are frequently fatal.
Case presentation: A 13-year-old Caucasian girl presented with progressive encephalopathy, hyperammonemic
coma and lactic acidosis. She had a history of intermittent regular episodes of nausea and vomiting from seven
years of age, previously diagnosed as abdominal migraines. At presentation she was hyperammonemic (ammonia
477 μmol/L) with no other biochemical indicators of hepatic dysfunction or damage and had grossly elevated
urinary orotate (orotate/creatinine ratio 1.866 μmol/mmol creatinine, reference range <500 μmol/mmol creatinine)
highly suggestive of ornithine transcarbamylase deficiency. She was treated with intravenous sodium benzoate and
arginine and made a rapid full recovery. She was discharged on a protein-restricted diet. She has not required
ongoing treatment with arginine, and baseline ammonia and serum amino acid concentrations are within normal
ranges. She has had one further episode of hyperammonemia associated with intercurrent infection after one year
of follow up. An R40H (c.119G>A) mutation was identified in the ornithine transcarbamylase gene (OTC) in our
patient confirming the first symptomatic female shown heterozygous for the R40H mutation. A review of the
literature and correspondence with authors of patients with the R40H mutation identified one other symptomatic
female patient who died of hyperammonemic coma in her late teens.
Conclusions: This report expands the clinical spectrum of presentation of ornithine transcarbamylase deficiency to
female heterozygotes for the hypomorphic R40H OTC mutation. Although this mutation is usually associated with a
mild phenotype, females with this mutation can present with acute decompensation, which can be fatal. Ornithine
transcarbamylase deficiency should be considered in the differential diagnosis of unexplained acute confusion,
even without a suggestive family history.
Introduction
Ornithine transcarbamylase deficiency (OTCD, online
mendelian inheritance in man: OMIM #311250) is the
most common hereditary urea cycle defect and is inher-
ited in an X-linked manner [1,2]. It classically presents
with encephalopathy and hyperammonemia, manifesting
as tachypnea, lethargy, nausea, vomiting, behavioral
changes, confusion, encephalopathy, seizures, coma, and
death. There is a wide phenotypic spectrum from neona-
tal hyperammonemic coma to asymptomatic adults [3-5].
Male hemizygotes with null alleles present with fatal
hyperammonemic neonatal encephalopathy. Treatment
with survival in this group results in severe neurological
impairment in almost all cases [6]. Males with hypo-
morphic mutations and female heterozygotes usually pre-
sent later, some not until late adulthood [5,7-9].
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encephalopathic episodes, a significant proportion of
which are fatal [10]. Later onset patients may, in retro-
spect, have a history of self-restricted protein intake or
episodes of nausea and vomiting due to transient hyper-
ammonemia. Typical triggers are excessive protein load,
including total parenteral nutrition in previously undiag-
nosed individuals [11], catabolic stress, the postpartum
period [12], and certain drugs, notably sodium valproate
[13]. The diagnosis can be made on elevated serum
ammonia with high urinary orotate. The aim of treat-
ment of episodes of decompensation is to reduce ammo-
nia levels with sodium benzoate or phenylbutyrate that
increase alternate ammonia excretion, arginine replace-
ment and protein restriction. Hemodialysis or hemofiltra-
tion is indicated in severe cases. Future episodes are
reduced with dietary protein restriction, oral benzoate or
phenylbutyrate and arginine supplementation.
Case presentation
Our patient was a previously well 13-year-old Caucasian
girl, referred to our metabolic service from intensive
care because of unexplained encephalopathy and lactic
acidosis. She presented to the emergency department
with a two-day history of vomiting and deteriorating
mentation, progressing to confusion. Initial physical
examination was unremarkable except for decreased
conscious level. There was no hepatomegaly or signs of
chronic liver disease. Initial venous blood gas analysis
demonstrated a respiratory alkalosis (pH 7.488, pCO2
29.9 mmHg, bicarbonate 22.5 mmol/L, standard base
excess -0.5 mmol/L), mild lactic acidemia (lactate 2.6
mmol/L) and normoglycemia (glucose 5.7 mmol/L). Her
alanine aminotransferase (ALT) was mildly elevated at
53 U/L (reference range <45 U/L) but other liver func-
tion tests, international normalized ration (INR) and
activated partial thromboplastin time (APTT), electro-
lytes, urea, creatinine, amylase, lipase, full blood count,
erythrocyte sedimentation rate (ESR), and C-reactive
protein, were all within the normal ranges. There was
no history of drug or toxin ingestion and a urinary drug
screen did not detect any amphetamines, cocaine, can-
nabis or opiates. A lumbar puncture and cerebral com-
puted tomography (CT) scan were normal. She was
admitted to the intensive care unit for observation
because of her decreased level of consciousness, com-
menced on intravenous fluids (0.45% saline and 5% dex-
trose) and broad-spectrum antimicrobials to cover sepsis
and central nervous system infection after appropriate
cultures had been taken. She became increasingly agi-
tated and confused, developed opisthotonos and a signif-
icant lactic acidosis without hypoglycemia (pH 7.387,
pCO2 32.1 mmHg, bicarbonate 18.9 mmol/L, standard
base excess -5.2 mmol/L, glucose 8.2, lactate 9.5 mmol/L).
Serum ammonia was 477 μmol/L, suggesting a urea cycle
defect. She was treated with intravenous sodium benzoate
(loading dose of 250 mg/kg followed by an infusion at 250
mg/kg/day), arginine (200 mg/kg/day), 10% dextrose and
lipid infusions. Biochemical markers improved rapidly,
with the ammonia falling to 208 μmol/L within three
hours. The urine metabolic screen showed a gross eleva-
tion in orotate (orotate/creatinine ratio 1.866 μmol/mmol
creatinine, reference range <500 μmol/mmol creatinine),
and plasma quantitative amino acid analysis showed a
typical picture associated with OTCD. Clinically she
became more alert and recovered with normal mentation
over four to five days. A large protein load consumption
associated with festivities was subsequently identified as
the trigger for her decompensation. She was put on a pro-
tein-restricted diet at maximum protein intake of 2 g/kg/
day. A detailed dietary history revealed that she had been
subtly self-restricting her protein intake to approximately
this level beforehand.
Further history elucidated frequent episodes of nausea
and vomiting from about seven years of age, two to
three times per week, particularly after restaurant meals
or after exercise. There were also shorter episodes of
nausea relieved after vomiting. A gastroenterologist had
made a diagnosis of abdominal migraines. Psychomotor
development was normal: she was in the appropriate
academic year at school, was well coordinated and a
good athlete. She is the youngest of four children born
to non-consanguineous Caucasian parents. Her mother
experienced migraines. A great uncle through the
maternal line died as a baby of unknown cause. No rela-
tives were known to have had similar episodes of nau-
sea, vomiting or confusion. Cascade testing of other
family members after appropriate genetic counseling is
proceeding.
Dietary protein restriction has resulted in no recur-
rence of her episodes of nausea and vomiting. Her
serum amino acids and ammonia levels have been
within normal ranges on dietary restriction alone and
she has not required oral treatment with phenylbutyrate
or arginine.
The family was given a written emergency plan. She
has had one episode of mild hyperammonemia (maxi-
mum ammonia 105 μmol/L) associated with vomiting
due to a gastrointestinal illness, from which she made a
full recovery. She has also had an episode of viral myosi-
tis since her initial admission, without developing neuro-
logical symptoms or signs. She shows no demonstrable
adverse effects on her growth or development.
Discussion
A review of the literature identified another family with
symptomatic females presumed carriers for the R40H
OTC mutation. The index case was a 17-year-old Japanese
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and vomiting, became confused, developed depressed level
of consciousness, then seizures and died on the second
day of hospital admission [7]. He was posthumously
shown to have the R40H mutation [14]. The family history
revealed that his younger sister had experienced two epi-
sodes of nausea and vomiting aged 13 each lasting one
week [7]. The mother was asymptomatic but had mild
protein load induced orotic aciduria. Clinical follow-up of
the younger sister was complicated by suboptimal compli-
ance. Unfortunately, she died aged 18 after hyperammone-
mic coma, having presented after festive protein ingestion.
It has not been possible to obtain molecular confirmation
that she and her mother are manifesting carriers of the
R40H OTC mutation. However, her clinical course, her
mother’s biochemical investigations and family history
strongly suggest this conclusion.
Manifestations of OTCD are highly variable and
depend upon the severity of the mutation and sex of the
individual. The classic presentation is males with hemi-
zygous null mutations with no residual enzyme activity
who present in the neonatal period with progressive
metabolic encephalopathy due to hyperammonemia with
death in the first week of life. Milder mutations with
varying degrees of residual enzyme activity produce later
onset from the first year of life to adulthood. Some
adults remain apparently asymptomatic, with protein
aversion their only symptom. Female heterozygotes have
an even wider spectrum of disease due to variable X-
inactivation in the liver. Specific triggers for encephalo-
pathic episodes are high protein loads, pregnancy and
certain drugs, including valproate. It is important to
recognize OTCD in later onset cases as the first presen-
tation is frequently fatal [10].
The risk of female heterozygotes developing symptoms
is difficult to quantify, posing practical problems for
management. Historical data are limited since diagnosis
is generally through affected males, suggesting that
female heterozygotes infrequently manifest symptoms.
X-inactivation studies on blood may not truly reflect
hepatic skewing and are therefore not reliable in pre-
dicting risk of hyperammonemic episodes in female het-
erozygotes [15]. X-inactivation studies on liver biopsies
might give more information but carry the risk of proce-
dure related morbidity. Our approach when counseling
family members has been to offer at risk males and
females genetic testing, regardless of age, and to take a
history specifically for exposure to significant known
triggers.
Conclusions
Females heterozygous for the R40H OTC mutation
should be considered at risk for hyperammonemic epi-
sodes, and should have appropriate counseling,
biochemical surveillance and treatment, institution of an
emergency treatment plan to prepare for possible hyper-
ammonemic episodes and monitoring during the post-
partum period.
More generally, for patients presenting with unex-
plained confusion or decreased level of consciousness,
urea cycle defects and in particular OTC should be con-
sidered in the differential diagnosis and an urgent
ammonia level determined.
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